Your browser doesn't support javascript.
loading
Lifting COVID-19 mitigation measures in Spain (May-June 2020).
Monge, Susana; Zamalloa, Pello Latasa; Moros, María José Sierra; Olaso, Oscar Pérez; Miguel, Lucía García San; Varela, Carmen; Ariza, Silvia Rivera; Torres, María C Vázquez; Lucerón, María Del Carmen Olmedo; Yuste, Paloma González; Crespo, Pilar Soler; Pozo, Javier Segura Del; Gullón, Pedro; Carrasco, José Miguel; Sánchez, Elena Vanessa Martínez; Bravo, Lidia Redondo; Castañeda, Myriam Pichiule; Hermida, María Jesús Purriños; Vidal, Xurxo Hervada; Gonzalez, Ismael Huerta; Margolles, Mario; Luna, Hermelinda Vanaclocha; Gómara, Enrique Ramalle; Martín, Jaime Jesús Pérez; López, María Dolores Chirlaque; Fernández, María Jesús López; Lorusso, Nicola; Ubago, Alberto Carmona; Perez, Ana Rivas; Marin, Violeta Ramos; Alvarez, Juan José Criado; Pérez, Daniel Castrillejo; Anés, Atanasio A Góméz; Frontera, Marga; Rodriguez, Pedro Macias; León, Eva Elisa Álvarez; Casañas, Miriam Díaz; Perez, Maria Angeles Lopaz; Ágreda, Juan Pablo Alonso Pérez de; Gutierrez, Paloma Navas; Aguilar, Ignacio Rosell; Axpe, Jose Mª Arteagoitia; Carril, Fernando Gonzalez; Azcárraga, Pilar Aparicio; Soria, Fernando Simón; Rodríguez, Berta Suarez.
Afiliação
  • Monge S; Ministry of Health, Madrid, Spain. Electronic address: smonge@mscbs.es.
  • Zamalloa PL; Ministry of Health, Madrid, Spain.
  • Moros MJS; Ministry of Health, Madrid, Spain.
  • Olaso OP; Ministry of Health, Madrid, Spain.
  • Miguel LGS; Ministry of Health, Madrid, Spain.
  • Varela C; National Centre of Epidemiology, Instituto de Salud Carlos III, CIBER Epidemiología y Salud Pública, Madrid, Spain.
  • Ariza SR; Ministry of Health, Madrid, Spain.
  • Torres MCV; Ministry of Health, Madrid, Spain.
  • Lucerón MDCO; Ministry of Health, Madrid, Spain.
  • Yuste PG; Ministry of Health, Madrid, Spain.
  • Crespo PS; Ministry of Health, Madrid, Spain.
  • Pozo JSD; Madrid Salud (Madrid Council Public Health Agency), Madrid, Spain.
  • Gullón P; APLICA Investigación y Traslación Soc Coop Mad, Madrid, Spain.
  • Carrasco JM; APLICA Investigación y Traslación Soc Coop Mad, Madrid, Spain.
  • Sánchez EVM; Ministry of Health, Madrid, Spain.
  • Bravo LR; Ministry of Health, Madrid, Spain.
  • Castañeda MP; Ministry of Health, Madrid, Spain.
  • Hermida MJP; General Directorate of Public Health, Autonomous Community of Galicia, Spain.
  • Vidal XH; General Directorate of Public Health, Autonomous Community of Galicia, Spain.
  • Gonzalez IH; General Directorate of Public Health, Principality of Asturias, Spain.
  • Margolles M; General Directorate of Public Health, Principality of Asturias, Spain.
  • Luna HV; Subdirectorate of Epidemiology and Public Health Surveillance, Autonomous Community of Valencia, Spain.
  • Gómara ER; General Directorate of Public Health, Consumption and Care, Autonomous Community of La Rioja, Spain.
  • Martín JJP; General Directorate of Public Health and Addictions, Region of Murcia, Spain.
  • López MDC; General Directorate of Public Health and Addictions, Region of Murcia, Spain.
  • Fernández MJL; Extremadura Health Service, Autonomous Community of Extremadura, Spain.
  • Lorusso N; General Directorate of Public Health and Pharmacy, Autonomous Community of Andalusia, Spain.
  • Ubago AC; General Directorate of Public Health and Pharmacy, Autonomous Community of Andalusia, Spain.
  • Perez AR; Ministry of Health, Autonomous City of Ceuta, Spain.
  • Marin VR; Ministry of Health, Autonomous City of Ceuta, Spain.
  • Alvarez JJC; Health Sciences Institute of Castile-La Mancha, Autonomous Community of Castile-La Mancha, Spain.
  • Pérez DC; General Directorate of Public Health and Consumption, Autonomous City of Melilla, Spain.
  • Anés AAG; General Directorate of Public Health and Consumption, Autonomous City of Melilla, Spain.
  • Frontera M; Ministry of Health, Balearic Islands, Spain.
  • Rodriguez PM; Ministry of Health, Balearic Islands, Spain.
  • León EEÁ; General Directorate of Public Health, Canary Islands, Spain.
  • Casañas MD; General Directorate of Public Health, Canary Islands, Spain.
  • Perez MAL; General Directorate of Public Health, Autonomous Community of Madrid, Spain.
  • Ágreda JPAP; General Directorate of Public Health, Autonomous Community of Aragón, Spain.
  • Gutierrez PN; General Directorate of Public Health, Autonomous Community of Cantabria, Spain.
  • Aguilar IR; General Directorate of Public Health, Autonomous Community of Castilla y León, Spain.
  • Axpe JMA; General Directorate of Public Health and Addictions, Basque Country, Spain.
  • Carril FG; General Directorate of Public Health and Addictions, Basque Country, Spain.
  • Azcárraga PA; Ministry of Health, Madrid, Spain.
  • Soria FS; Ministry of Health, Madrid, Spain.
  • Rodríguez BS; Ministry of Health, Madrid, Spain.
Article em En, Es | MEDLINE | ID: mdl-34274154
ABSTRACT

INTRODUCTION:

The state of alarm was declared in Spain due to the COVID-19 epidemic on March 14, 2020, and established population confinement measures. The objective is to describe the process of lifting these mitigation measures.

METHODS:

The Plan for the Transition to a New Normality, approved on April 28, contained four sequential phases with progressive increase in socio-economic activities and population mobility. In parallel, a new strategy for early diagnosis, surveillance and control was implemented. A bilateral decision mechanism was established between the Spanish Government and the autonomous communities (AC), guided by a set of qualitative and quantitative indicators capturing the epidemiological situation and core capacities. The territorial units were established ad-hoc and could be from Basic Health Zones to entire AC.

RESULTS:

The process run from May 4 to June 21, 2020. AC implemented plans for reinforcement of core capacities. Incidence decreased from a median (50% of territories) of 7.4 per 100,000 in 7 days at the beginning to 2.5 at the end. Median PCR testing increased from 53% to 89% of suspected cases and PCR total capacity from 4.5 to 9.8 per 1000 inhabitants weekly; positivity rate decreased from 3.5% to 1.8%. Median proportion of cases with traced contacts increased from 82% to 100%.

CONCLUSION:

Systematic data collection, analysis, and interterritorial dialogue allowed adequate process control. The epidemiological situation improved but, mostly, the process entailed a great reinforcement of core response capacities nation-wide, under common criteria. Maintaining and further reinforcing capacities remained crucial for responding to future waves.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En / Es Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En / Es Ano de publicação: 2021 Tipo de documento: Article